TY - JOUR
T1 - Potassium channel openers
T2 - Therapeutic potential in cardiology and medicine
AU - Jahangir, A.
AU - Terzic, A.
AU - Shen, W. K.
N1 - Funding Information:
Arshad Jahangir is a recipient of the CR75 Award from the Mayo Foundation and the Merck Award in Basic Sciences from the Society of Geriatric Cardiology. Andre Terzic is an Established Investigator of the American Heart Association. Work in the authors’ laboratory was partly supported by the National Institutes of Health, American Heart Association, Miami Heart Research Institute, the Bruce & Ruth Rappa-port Program in Vascular Biology and Gene Delivery and the Marriott Foundation.
PY - 2001
Y1 - 2001
N2 - Potassium (K+) channel openers (KCOs) define a class of chemically diverse agents that share a common molecular target, the metabolism-regulated ATP-sensitive K+ (KATP) channel. In view of the unique function that KATP channels play in the maintenance of cellular homeostasis, this novel class of ion channel modulators adds to existent pharmacotherapy with potential in promoting cellular protection under conditions of metabolic stress. Indeed, experimental studies have demonstrated broad therapeutic potential for KCOs, including roles as cardioprotective agents, vasodilators, bronchodilators, bladder relaxants, anti-epileptics, insulin secretagogues and promoters of hair growth. However, clinical experience with these drugs is limited and their place in patient management needs to be fully established.
AB - Potassium (K+) channel openers (KCOs) define a class of chemically diverse agents that share a common molecular target, the metabolism-regulated ATP-sensitive K+ (KATP) channel. In view of the unique function that KATP channels play in the maintenance of cellular homeostasis, this novel class of ion channel modulators adds to existent pharmacotherapy with potential in promoting cellular protection under conditions of metabolic stress. Indeed, experimental studies have demonstrated broad therapeutic potential for KCOs, including roles as cardioprotective agents, vasodilators, bronchodilators, bladder relaxants, anti-epileptics, insulin secretagogues and promoters of hair growth. However, clinical experience with these drugs is limited and their place in patient management needs to be fully established.
KW - ATP-sensitive potassium channels
KW - Alopecia
KW - Angina pectoris
KW - Asthma
KW - Hypertension
KW - Impotence
KW - Ischaemic heart disease
KW - Neuroprotection
KW - Peripheral vascular disease
UR - http://www.scopus.com/inward/record.url?scp=0035203468&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035203468&partnerID=8YFLogxK
U2 - 10.1517/14656566.2.12.1995
DO - 10.1517/14656566.2.12.1995
M3 - Review article
C2 - 11825331
AN - SCOPUS:0035203468
SN - 1465-6566
VL - 2
SP - 1995
EP - 2010
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
IS - 12
ER -